Aims: Although COVID-19 disease has many effects on patients after recovery, it is not known whether these effects are part of the recovery process or trigger other diseases. This study has aimed to investigate whether ferritin, which is used as an acute phase reactant to determine the severity and prognosis of the disease, has a role in determining the symptoms that occur after the disease. Methods: The study was conducted with 300 patients who were hospitalized with PCR positive and lung involvement. Patients' hospital admissions and initial ferritin levels were recorded within 6 months of discharge. It was examined whether there was a relationship between ferritin levels and the re-admission reasons. Results: 177(59.0) people had no symptoms during the six-month period and 123(41.0) patients were admitted to the hospital due to various symptoms. 6(2.0) of the patients became ex within six months after discharge. The most common symptoms in patients were 28(9.3) shortness of breath, 22(7.3) myalgia, 15(5.0) chest pain, 10(3.3) headache and 10(3.3) palpitations, respectively. Ferritin levels were found to be high in those with no symptoms and low in those with symptoms. Conclusion: Determining the symptoms, re-admissions, mortality rates and predictors that will guide Covid -19 is very important for the recognition, treatment and follow-up of this disease after discharge. More studies are needed to make a prediction according to ferritin levels in the process after recovery from Covid-19.

Splenic artery aneurysm is a rare and usually asymptomatic disease that is more common among women. It is usually diagnosed as a result of rupture during pregnancy. It may result in mortality if patients with rupture are not diagnosed and treated early. Although the endovascular method is the first choice in treatment, the surgical procedure can also be applied in hemodynamically unstable patients. In this report, we present a case of splenic artery aneurysm rupture that occurred due to the use of enoxaparin in a patient diagnosed with COVID-19 and followed up at home.

Colchicine is used in the treatment of many diseases. It should be used very carefully as the treatment dose and toxic dose are very close to each other and may lead to multiorgan failure. Although colchicine toxicity is usually seen in suicidal use, it may also occur when used in therapeutic doses. In this report, we present a case of a 70-year-old patient who used colchicine due to pericardial effusion over two months and died from multiorgan failure, to draw attention to colchicine toxicity due to using it in therapeutic doses.